Advanced Search
Contact | Corporate | Help

RAD001 and Erlotinib in Patients With Neuroendocrine Tumors

Sponsors:
  • University of California, San Francisco
  • Genentech
  • Novartis Pharmaceuticals
  • V Foundation for Cancer Research
Phases:
  • Phase II
IndicationsAcronym:
  • Neuroendocrine Tumors
Age Groups:
  • Adult
  • Senior
Gender:
Both
Names:
  • Drug: everolimus (RAD001)
  • Drug: erlotinib
Enrollment:
44

Additional information about NCT00843531.


SourceSolution © 2008-2012